Demographic and clinical characteristics
Female sex, n (%) 14 (42%)
Age (median years, IQR) 36 (31-42)
Baseline BMI (median kg/m2, IQR) 16.7 (15.4-17.6)
Week 12 BMI (median kg/m2, IQR) 17.6 (16.5-19.0)a
Baseline CD4+ count (median cells/μl, IQR) 224 (151-256)
Week 12 CD4+ count (median cells/μl, IQR) 349 (275-426)a
Median serum, urine, and cardiovascular values pre-treatment and after 12 weeks of antiretroviral therapy, median (IQR)
Variable Recruitment Week 12 of ART
C-reactive protein (mg/l) 18.3 (4.5-64.8) 6.4 (3.8-19.7)a
TNF-α receptor 1 (ng/ml) 1.3 (0.8-2.4) 1.0 (0.6–1.3)a
Soluble CD163 (ng/ml) 684 (511-1022) 531 (376-1040)
Soluble CD14 (μg/ml) 2.4 (2.1-2.7) 2.5 (2.0-3.1)
Isoprostane-to-creatinine ratio 0.02 (0.01-0.05) 0.09 (0.05-0.24)a
Augmentation Index 11.9 (1.0-30.0) 19.0 (0.1-25.9)
Reactive Hyperemia Index 0.6 (0.3-0.8) 0.6 (0.4-0.7)
QTc (ms) 434 (421-447) 431 (417-446)
RMSSD (ms) 26.4 (17.5-41.3) 37.2 (19.2-71.6)a
Triangular Index 6.8 (5.9-10.6) 9.6 (6.1-14.5)
Low frequency variations (ms2) 130.2 (85.0-151.9) 112.9 (76.1-151.6)
High frequency variations (ms2) 214.7 (154.7-260.8) 232.6 (169.7-327.1)
Power Ratio 0.6 (0.4-0.9) 0.4 (0.3-0.9)
Systolic blood pressure (mm Hg) 100 (93-110) 110 (100-120)a
Diastolic blood pressure (mm Hg) 60 (60-70) 70 (60-70)
Heart rate (bpm) 78 (71-89) 68 (63-82)
Abbreviation: BMI: Body Mass Index; QTC: Corrected QT interval; RMSSD: Root Mean Square of the Successive Differences; TNF-α: Tumor Necrosis Factor-α. Reactive hyperemia index is natural log transformed a: p<0.05 for change at 12 weeks
Table 1: Description of the cohort (n=33).
Goto home»